Nanoform Partners with Revio Therapeutics
Nanoform Finland Plc announced a partnership with Revio Therapeutics to co-develop and commercialize GLIORA.
- GLIORA is a nano-formulated combination of olaparib and temozolomide.
- It will be administered locally as a long-acting, thermo-responsive hydrogel.
- The treatment targets high-grade glioma, a fast-growing and aggressive type of brain tumor.
GLIORA combines olaparib (Lynparza®) and temozolomide (Temodar®) for the treatment of glioma.
Nanoform Finland Plc is a medicine performance-enhancing company.
Author's summary: Nanoform partners with Revio Therapeutics to develop GLIORA for glioma treatment.
More News
- 2 US Navy aircraft crash in South China Sea
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Biopic reintroduces female revolutionary hero - BusinessWorld Online
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- West Indies ease past Bangladesh in first T20I
- The environmental impact of the 2026 World Cup
- Wallingford deli asks for help to keep feeding people in need
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia